Levosimendan: A unique approach to the treatment of heart failure

Heart Disease

Volumn 4, Issue 4, 2002, Pages 265-271

  Nawarskas, James J ^a   Anderson, Joe R ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALCOHOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CALCIUM SENSITIZER; CAPTOPRIL; CARVEDILOL; DIGOXIN; DOBUTAMINE; FELODIPINE; ISOSORBIDE MONONITRATE; ITRACONAZOLE; LEVOSIMENDAN; MILRINONE; PHOSPHODIESTERASE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE INHIBITOR; PIMOBENDAN; PLACEBO; POTASSIUM CHANNEL; TROPONIN; UNCLASSIFIED DRUG; WARFARIN;

CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME INHIBITION; HEADACHE; HEART CONTRACTION; HEART FAILURE; HEART MUSCLE OXYGEN CONSUMPTION; HEMODYNAMICS; HUMAN; HYPOTENSION; INOTROPISM; MAJOR CLINICAL STUDY; MORTALITY; NAUSEA; REVIEW; SUDDEN DEATH; TACHYCARDIA; VASODILATATION;

EID: 0036632978     PISSN: 1521737X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00132580-200207000-00009     Document Type: Review

References (63)

1. Effect of oral milrinone on mortality in severe chronic heart failure
2. Intermittent dobutamine treatment in patients with chronic refractory congestive heart failure: A randomized, double-blind, placebo-controlled study
3. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo
4. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure
5. Treatment of severe heart failure: Quantity or quality of life? A trial of enoximone
6. Mechanisms of action of calcium-sensitizing drugs
7. A novel approach to the development of positive inotropic agents for chronic heart failure
8. Basic cardiac structure and function
9. Parenteral inotropic support for advanced congestive heart failure
10. Intravenous inotropic agents in the intensive therapy unit: Do they really make a difference?
11. 2+ transients in acquorin-loaded right-ventricular papillary muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit
12. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial
13. Effect of pimobendan on exercise capacity in patients with heart failure: Main results from the Pimobendan in Congestive Heart Failure (PICO) trial
14. Pharmacokinetics and pharmacodynamics of simendan, a novel calcium sensitizer, in healthy volunteers
15. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation
16. 2+-sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe and proton nuclear magnetic resonance study
17. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan
18. Further evidence for the cardiac troponin C mediated calcium sensitization by levosimendan: Structure-response and binding analysis with analogs of levosimendan
19. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium
20. 2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart
21. Drug binding to cardiac troponin C
22. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting
23. Myocardial efficiency during calcium sensitization with levosimendan: A noninvasive study with positron emission tomography and echocardiography in healthy volunteers
24. Myocardial efficiency during levosimendan infusion in congestive heart failure
25. Effects of levosimendan on myocardial contractility and oxygen consumption
26. Effects of repeated brief coronary occlusion on regional left ventricular function and dimension in dogs
27. Reversal of segmental hypokinesis by coronary angioplasty in patients with unstable angina, persistent T wave inversion, and left anterior descending coronary artery stenosis: Additional evidence for myocardial stunning in humans
28. Intracoronary levosimendan enhances contractile function of stunned myocardium
29. Cellular mechanisms of myocardial stunning
30. The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan
31. Effects of levosimendan on cardiac arrhythmia: Electrophysiologic and ambulatory electrocardiographic findings in phase II and phase III clinical studies in cardiac failure
32. + channel in rat arterial myocytes
33. + channel in rat ventricular cells
34. + channel opening: A new drug principle in cardiovascular medicine
35. Pharmacology of the potassium channel openers
36. Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels
37. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs
38. Pharmacological evidence for a role of ATP-dependent potassium channels in myocardial stunning
39. ATP channel opener bimakalim on coronary blood flow, monophasic action potential duration, and infarct size in dogs
40. ATP channels
41. Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein
42. Coronary vasorelaxant effect of levosimendan, a new inodilator with calcium-sensitizing properties
43. Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure
44. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure
45. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure
46. Efficacy and safety of intravenous levosimendan in severe low-output heart failure
47. Randomized study on safety and effectiveness of levosimendan in patients with left ventricular failure after an acute myocardial infarction
48. Effect of levosimendan, a calcium sensitizer, on the survival of hospitalized patients with heart failure
49. Levosimendan, a novel myofilament calcium sensitizer, allows weaning of parenteral inotropic therapy in patients with severe congestive heart failure
50. Safety of levosimendan and other calcium sensitizers
51. Levosimendan
52. Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril
53. No pharmacodynamic interactions between a new calcium sensitizing agent levosimendan and a calcium antagonist drug felodipine
54. A new calcium sensitizing agent levosimendan has no pharmacokinetic or pharmacodynamic interactions with warfarin
55. Pharmacokinetic and pharmacodynamic interactions between the novel calcium sensitiser levosimendan and warfarin
56. Haemodynamic interactions between the novel calcium sensitiser levosimendan and isosorbide-5-mononitrate in healthy subjects
57. Haemodynamic interactions between levosimendan and carvedilol in healthy subjects
58. Studies on psychomotoric effects and pharmacokinetic interactions of the new calcium sensitizing drug levosimendan and ethanol
59. The CYP3A4 inhibitor itraconazole does not affect the pharmacokinetics of a new calcium-sensitizing drug levosimendan